None of these products are licensed as medicines or approved for therapeutic applications
Importantly, the genetic and pharmacological inhibition of MT-1G enhances the anticancer activity of sorafenib in vitro and tumor xenograft models (Sun et al., 2016a)
Daily dose: 1,165mcg (1.165mg) total blend This breaks down to approximately: 850mcg GHK-Cu 165mcg TB-500 165mcg BPC-157 Administration: Once daily, subcutaneous injection Cycle length: 4 weeks initial assessment Schedule: Daily injection at a consistent time, preferably morning At this dose level, you're working with approximately half the standard protocol
This means you can safely stock several months of research supply without worrying about degradation, as long as the powder remains dry and sealed
Bianchi and colleagues tested oral ALC (1 g t.i.d.) for 8 weeks in 25 patients
However, most evidence continues to indicate associations and the particular chemical processes driving a majority of visible events remain unidentified (33)
